MA32566B1 - Anticorps neutralisant les cytomégalovirus humains et leurs utilisations - Google Patents

Anticorps neutralisant les cytomégalovirus humains et leurs utilisations

Info

Publication number
MA32566B1
MA32566B1 MA33620A MA33620A MA32566B1 MA 32566 B1 MA32566 B1 MA 32566B1 MA 33620 A MA33620 A MA 33620A MA 33620 A MA33620 A MA 33620A MA 32566 B1 MA32566 B1 MA 32566B1
Authority
MA
Morocco
Prior art keywords
antibodies
human cytomegaloviruses
neutralize human
hcmv
epitope
Prior art date
Application number
MA33620A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Antonio Lanzavecchia
Annalisa Macagno
Original Assignee
Humabs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Llc filed Critical Humabs Llc
Publication of MA32566B1 publication Critical patent/MA32566B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
MA33620A 2008-07-16 2011-02-15 Anticorps neutralisant les cytomégalovirus humains et leurs utilisations MA32566B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/002683 WO2010007463A1 (en) 2008-07-16 2008-07-16 Human cytomegalovirus neutralising antibodies and use thereof

Publications (1)

Publication Number Publication Date
MA32566B1 true MA32566B1 (fr) 2011-08-01

Family

ID=40430130

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33620A MA32566B1 (fr) 2008-07-16 2011-02-15 Anticorps neutralisant les cytomégalovirus humains et leurs utilisations

Country Status (17)

Country Link
EP (2) EP2960250A1 (https=)
JP (1) JP5475774B2 (https=)
KR (3) KR20140041951A (https=)
CN (1) CN102143974B (https=)
AU (1) AU2008359583B2 (https=)
BR (1) BRPI0822989A2 (https=)
CA (1) CA2730620A1 (https=)
EA (1) EA201170204A1 (https=)
ES (1) ES2548014T3 (https=)
IL (1) IL210352A0 (https=)
MA (1) MA32566B1 (https=)
MX (1) MX2011000542A (https=)
NZ (1) NZ591055A (https=)
PT (1) PT2303923E (https=)
TN (1) TN2010000616A1 (https=)
WO (1) WO2010007463A1 (https=)
ZA (1) ZA201100489B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
DK2352759T3 (en) 2008-07-16 2017-12-18 Inst Res Biomedicine ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUS AND USE THEREOF
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
LT4226941T (lt) 2010-08-31 2025-01-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
CN102286099B (zh) * 2011-08-05 2014-04-09 深圳市卫光生物制品股份有限公司 静注巨细胞病毒人免疫球蛋白及其制备方法
EP3613431B1 (en) * 2012-03-27 2023-01-11 Variation Biotechnologies Inc. Methods for detection of anti-cytomegalovirus neutralizing antibodies
CN110241137A (zh) * 2012-07-27 2019-09-17 希望之城 一种递送ul128复合体和预防cmv感染的mva疫苗
WO2014099908A1 (en) * 2012-12-17 2014-06-26 Genentech, Inc. Methods for inhibiting viral infection in transplant patients
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN107325178A (zh) * 2017-06-29 2017-11-07 佛山市南海区普罗圣塔生物科技有限公司 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CA3210091A1 (en) * 2021-02-05 2022-08-11 Amgen Inc. Non-terminal antibody discovery methods and single cell assays
CN116162154B (zh) * 2022-10-21 2024-06-11 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
AU590656B2 (en) * 1985-12-06 1989-11-09 Teijin Limited Anti cytomegaloviral human monoclonal antibody and process for its preparation
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1998057993A1 (en) 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
AU2005333155B2 (en) * 2005-03-14 2011-11-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against Hendra and Nipah viruses
EP3031469B1 (en) * 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof

Also Published As

Publication number Publication date
JP2011527899A (ja) 2011-11-10
KR101407216B1 (ko) 2014-06-16
AU2008359583B2 (en) 2012-04-05
CN102143974B (zh) 2015-03-25
EP2960250A1 (en) 2015-12-30
ZA201100489B (en) 2013-03-27
KR20150002895A (ko) 2015-01-07
KR20110055517A (ko) 2011-05-25
KR20140041951A (ko) 2014-04-04
EA201170204A1 (ru) 2011-08-30
ES2548014T3 (es) 2015-10-13
BRPI0822989A2 (pt) 2018-05-29
NZ591055A (en) 2012-08-31
IL210352A0 (en) 2011-03-31
CA2730620A1 (en) 2010-01-21
EP2303923A1 (en) 2011-04-06
WO2010007463A1 (en) 2010-01-21
AU2008359583A1 (en) 2010-01-21
TN2010000616A1 (en) 2012-05-24
CN102143974A (zh) 2011-08-03
JP5475774B2 (ja) 2014-04-16
PT2303923E (pt) 2015-08-25
MX2011000542A (es) 2011-08-03
EP2303923B1 (en) 2015-06-24

Similar Documents

Publication Publication Date Title
MA32566B1 (fr) Anticorps neutralisant les cytomégalovirus humains et leurs utilisations
MA31225B1 (fr) Anticorps neutralisants des cytomegalovirus humains et leur utilisation
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
MA32577B1 (fr) Anticorps neutralisants le virus de l'influenza a et leurs utilisations
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
MA34524B1 (fr) Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
MA40497A (fr) Anticorps et récepteurs antigéniques chimériques spécifiques du cd19
MA34749B1 (fr) Anticorps anti-récepteur de la barrière hémato-encéphalique à faible affinité et leurs utilisations
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MA33198B1 (fr) Anticorps anti-her di-spécifiques
MA34059B1 (fr) Thérapie anti-angiogénique pour le traitement du cancer des ovaires
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA33534B1 (fr) Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
MA37945B1 (fr) Anticorps humains dirigés contre le gfr?3 et méthodes d'utilisation associées
MA49727B1 (fr) Anticorps et polypeptides dirigés contre cd127
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
SG196835A1 (en) Human anti-b7rp1 neutralizing antibodies
MA28982B1 (fr) Anticorps antagonistes de il-17
MA33381B1 (fr) Proteine de liaison a il-13
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
EA200800812A1 (ru) Композиции антитела против cd3